|
|
- 2015
脂肪酸合成酶在胰腺癌细胞凋亡过程中的作用
|
Abstract:
摘要：目的 探讨脂肪酸合成酶(fatty acid synthase, FASN)对胰腺癌细胞凋亡的影响及其可能的分子机制。方法 应用Annexin V/FITC流式细胞仪检测脂肪酸合成酶受到抑制后对胰腺癌细胞株PANC-1凋亡水平的影响，qRT-PCR、Western blot技术检测受到C75作用后的胰腺癌细胞PANC-1中Caspase-3、Bcl-2、FASN蛋白及RNA的水平。结果 应用C75对PANC-1细胞中FASN进行特异性地抑制，随着C75浓度增加，胰腺癌细胞中脂肪酸合成酶蛋白表达量明显降低，细胞凋亡水平升高。同时，C75处理组Caspase-3分子水平较对照组升高，Bcl-2分子水平下降(P<0.05)。 结论 脂肪酸合成酶通过Bcl-2以及Caspase-3分子，参与了胰腺癌细胞株PANC-1中细胞凋亡的过程。因此，脂肪酸合成酶在未来可以作为药物靶点，用于临床治疗胰腺癌。
ABSTRACT: Objective To investigate the effect of fatty acid synthase (FASN) on apoptosis in pancreatic cancer cell PANC-1 and the possible molecular mechanism. Methods Annexin V/FITC and flow cytometry were performed to detect the expression of FASN in pancreatic cancer PANC-1 after C75 treatment and the change of apoptosis in pancreatic cancer cell PANC-1 treated with C75. Quantity reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot were used to measure the protein and RNA expressions of Caspase-3, bcl-2 and FASN. Results Inhibited by C75, the activity of FASN in pancreatic cancer cell PANC-1 was significantly decreased. Meanwhile, PANC-1 showed an increased apoptosis level in a dose-dependent manner (P<0.05). Furthermore, after C75 inhibited FASN in pancreatic cancer cells, the protein and RNA expressions of Caspase-3 significantly increased (P<0.05) whereas the level of Bcl-2 reduced (P<0.05). Conclusion FASN is involved in the process of apoptosis in PANC-1 via Bcl-2 and Caspase-3. Therefore, FASN will provide a new target for the treatment of pancreatic cancer and generate better treatment efficacy
| [1] | KNOWLES LM, AXELROD F, BROWNE CD, et al. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2[J]. J Biol Chem, 2004, 279(29):30540-30545. |
| [2] | SWINNEN JV, BRUSSELMANS K, VERHOEVEN G. Increased lipogenesis in cancer cells: new players, novel targets[J]. Curr Opin Clin Nutr Metab Care, 2006, 9(4):358-365. |
| [3] | CHIRALA SS, JAYAKUMAR A, GU ZW, et al. Human fatty acid synthase: role of interdomain in the formation of catalytically active synthase dimer[J]. Proc Natl Acad Sci USA, 2001, 98(6):3104-3108. |
| [4] | RANGAN VS, JOSHI AK, SMITH S. Mapping the functional topology of the animal fatty acid synthase by mutant complementation ？？in vitro？？[J]. Biochemistry, 2001, 40(36):10792-10799. |
| [5] | MENENDEZ JA, LUPU R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis[J]. Nat Rev Cancer, 2007, 7(10):763-777. |
| [6] | LITTLE JL, KRIDEL SJ. Fatty acid synthase activity in tumor cells[J]. Subcell Biochem, 2008, 49:169-194. |
| [7] | HUNT DA, LANE HM, ZYGMONT ME, et al. MRNA stability and overexpression of fatty acid synthase in human breast cancer cell lines[J]. Anticancer Res, 2007, 27(1A):27-34. |
| [8] | SHURBAJI MS, KALBFLEISCH JH, THURMOND TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer[J]. Hum Pathol, 1996, 27(9):917-921. |
| [9] | GANSLER TS, HARDMAN W, 3RD, HUNT DA, et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival[J]. Hum Pathol, 1997, 28(6):686-692. |
| [10] | PIYATHILAKE CJ, FROST AR, MANNE U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung[J]. Hum Pathol, 2000, 31(9):1068-1073. |
| [11] | HORIGUCHI A, ASANO T, ITO K, et al. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells[J]. J Urol, 2008, 180(2):729-736. |
| [12] | WITKIEWICZ AK, NGUYEN KH, DASGUPTA A, et al. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome[J]. Cell Cycle, 2008, 7(19):3021-3025. |
| [13] | SWIERCZYNSKI J, HEBANOWSKA A, SLEDZINSKI T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer[J]. World J Gastroenterol, 2014, 20(9):2279-2303. |
| [14] | JONES S, ZHANG X, PARSONS DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. Science, 2008, 321(5897):1801-1806. |
| [15] | LIU H, LIU JY, WU X, et al. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker[J]. Int J Biochem Mol Biol, 2010, 1(1):69-89. |
| [16] | YANG Y, LIU H, LI Z, et al. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers[J]. Int J Biochem Mol Biol, 2011, 2(1):89-98. |
| [17] | ALO PL, AMINI M, PIRO F, et al. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma[J]. Anticancer Res, 2007, 27(4B):2523-2527. |
| [18] | HARRINGTON HA, HO KL, GHOSH S, et al. Construction and analysis of a modular model of caspase activation in apoptosis[J]. Theor Biol Med Model, 2008, 5(1):26-41. |
| [19] | SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1):9-29. |
| [20] | KLEIN AP. Identifying people at a high risk of developing pancreatic cancer[J]. Nat Rev Cancer, 2013, 13(1):66-74. |
| [21] | SMITH S, WITKOWSKI A, JOSHI AK. Structural and functional organization of the animal fatty acid synthase[J]. Prog Lipid Res, 2003, 42(4):289-317. |
| [22] | LI JN, Gorospe M, Chrest FJ, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53[J]. Cancer Res, 2001, 61(4):1493-1499. |
